Cell Therapeutics, Inc.

Genentech, Inc.

Other

Fred Hutchinson Cancer Center

Genetech, Inc.

David W Leung

David M Hollenback

J Peter Klein

Christopher K Tompkins

Daniel Adourel

William I Wood

James William West

Gail E Underiner

Jack W Singer

Glenn C Rice

John E Tulinsky

R Glenn Hammonds, Jr

Baoqing Gong

Steven A Spencer

Thayer H White

Lynn Bonham

Scott A Shaffer

Robert E Finney

Norina M Tang

David V Goeddel

Anil M Kumar

Marc Besman

Stewart D Chipman

Reitha Weeks

Napoleone Ferrara

George J Todaro

David W Martin, Jr

Ronald A Hitzeman

Peter Cameron Colosi

Timothy M Rose

Lance H Ridgers

Disclosed are biologically active protein conjugates that comprise a biologically active polypeptide coupled via a peptide bond to a polypeptide comprising from 2 to about 500 units of a repeating peptide motif, wherein the biologically active protein conjugate exhibits a modified plasma half-life compared to the intrinsic half-life of the unconjugated biologically active polypeptide or protein. Also disclosed are methods of making and using the conjugated proteins, as well as methods for determining whether a given conjugate exhibits a modified half life relative to the intrinsic half life of the unconjugated polypeptide.

Conjugates of biologically active polypeptides having an increased in vivo half-life

Conjugates of biologically active proteins having a modified in vivo half-life

The invention relates to triazines and the use thereof to inhibit lysophosphatidic acid acyltransferase &#x3b2; (LPAAT-&#x3b2;) activity. The invention further relates to methods of treating cancer using said triazines. The invention also relates to methods for screening for LPAAT-&#x3b2; activity.

LPAAT-&#x3b2; inhibitors and uses thereof

This invention relates to a biotechnology invention concerning human phosphatidic acid phosphatase. More particularly, this invention relates to three variants of human phosphatidic acid phosphatase namely PAP-&#x3b1;(1 and 2), PAP-&#x3b2; and PAP-&#x3b3; and uses thereof.

Human phosphatidic acid phosphatase

Polypeptides are obtained, for example, via expression of encoding cDNA sequences, that have the activity of the enzyme lysophosphatidic acid acyltransferase (LPAAT), also known as 1-acyl sn-glycerol-3-phosphate acyltransferase.

Human lysophoshatidic acid acyltransferase gamma-1 polypeptide

Human lysophosphatidic acid acyltransferase gamma-2 polypeptide

Method of screening compounds that inhibit lysophosphatidic acid acyltransferase

There is disclosed cDNA sequences and polypeptides having the enzyme CDP-diacylglycerol synthase (CDS) activity. CDS is also known as CTP:phosphatidate cytidylyltransferase. There is further disclosed methods for isolation and production of polypeptides involved in phosphatidic acid metabolism and signaling in mammalian cells, in particular, the production of purified forms of CDS.

Mammalian CDP-diacylglycerol synthase

Mammalian lysophosphatidic acid acyltransferase

Three new isoforms of phosphatidylcholine phospholipase D, hPLD2.1, hPLD2.2 and hPLD1.5, can be produced recombinantly and are useful for screening compounds, as drug candidates, for an ability to modify PCPLD activity.

Phosphatidylcholine phospholipase D

Therapeutic hybrid cytokines, having a size ranging from about 10 to about 30 kDa, comprise portions of cytokines: leukemia inhibitory factor (LIF), granulocyte-colony stimulating factor (G-CSF), interleukin-6 (IL-6), interleukin-11 (IL-11), oncostatin-M (OSM), and ciliaryneurotrophic factor (CNTF). Hybrid cytokines comprise three or four &agr;-helical sequences selected from &agr;-helical sequences of IL-6, G-CSF, LIF, IL-11, CNTF and OSM and linking sequences of 5-40 amino acids in length, selected from the linking sequences of IL-6, G-CSF, LIF, IL-11, CNTF and OSM or other, desirable linking sequences. In the hybrid cytokines, at least one &agr;-helical sequence is derived from a different cytokine than at least one other &agr;-helical sequence; or, at least one linking sequence of a cytokine differentiates the hybrid cytokine from a corresponding cytokine. In hybrid cytokines having three &agr;-helical sequences selected from the group of cytokines listed, a possible fourth sequence may not correspond to any &agr;-helical sequence in any of the cytokines. Hybrid cytokines, radically different from any corresponding cytokines, have unexpected advantages in selective biological mechanisms over a much broader range of biological activities than exhibited by cytokines.

Hybrid cytokines

There is disclosed cDNA sequences and polypeptides having the enzyme lysophosphatidic acid acyltransferase (LPAAT) activity. LPAAT is also known as 1-acyl sn-glycerol-3-phosphate acyltransferase.

Growing community of inventors

Mercer Island, WA, United States of America

David W Leung